Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 7/2/12 → 6/30/14 |
Funding
- Vertex Pharmaceuticals Inc: $14,288.00
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects with Cystic Fibrosis who have the R117H-CFTR Mutation
- Anstead, Michael (PI)
- Danov, Zoran (CoI)
- Kanga, Jamshed (CoI)